Cipla Ltd.

Cipla has informed about Press Release dated June 01, 2015 titled ‘Stempeutics receives Orphan Drug Designation (ODD) in the European Union for its novel stem cell drug ‘Stempeucel’ for the treatment of Thromboangiitis Obliterans’.

The above information is a part of company’s filings submitted to BSE.